Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3Gynecologic 1

Conditions

Uterine Cervical Neoplasms 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Endometrial Neoplasms 1

Interventions

pembrolizumab 17Carboplatin 10Paclitaxel 7Trastuzumab 5Nivolumab 5Gemcitabine 5Early Intervention, Educational 5Cyclophosphamide 5Cisplatin 5fludarabine 4cemiplimab 4Psychiatric Rehabilitation 4Fluorouracil 4Docetaxel 4Counseling 4Albumin-Bound Paclitaxel 4tisotumab vedotin 3belinostat 3Radiotherapy 3Polymerase Chain Reaction 3Methods 3Magnetic Resonance Spectroscopy 3Gene Expression Profiling 3Fluorodeoxyglucose F18 3Biopsy 3zimberelimab 2ulixertinib 2pertuzumab 2palbociclib 2osimertinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × ferumoxtran-10 × Gynecologic × Clear all
NCT00188695 2022-10-07

Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide

University Health Network, Toronto

Phase 1/2 Completed
61 enrolled
GenitourinaryGynecologic

Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Prostatic Neoplasms, Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡